Nothing Special   »   [go: up one dir, main page]

WO2011016686A3 - Prasugrel disulfonate or crystalline forms thereof, method for preparing same, and pharmaceutical composition containing same - Google Patents

Prasugrel disulfonate or crystalline forms thereof, method for preparing same, and pharmaceutical composition containing same Download PDF

Info

Publication number
WO2011016686A3
WO2011016686A3 PCT/KR2010/005149 KR2010005149W WO2011016686A3 WO 2011016686 A3 WO2011016686 A3 WO 2011016686A3 KR 2010005149 W KR2010005149 W KR 2010005149W WO 2011016686 A3 WO2011016686 A3 WO 2011016686A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
prasugrel
disulfonate
pharmaceutical composition
composition containing
Prior art date
Application number
PCT/KR2010/005149
Other languages
French (fr)
Other versions
WO2011016686A2 (en
Inventor
Chang Hee Park
Jong Ouk Baek
Hee Sook Oh
Mi Kyoung Lee
Chang Ju Choi
Tae Hee Ha
Kwee Hyun Suh
Gwan Sun Lee
Original Assignee
Hanmi Holdings Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co., Ltd. filed Critical Hanmi Holdings Co., Ltd.
Publication of WO2011016686A2 publication Critical patent/WO2011016686A2/en
Publication of WO2011016686A3 publication Critical patent/WO2011016686A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a stable and non-hygroscopic prasugrel disulfonate or a crystalline form thereof; a method for preparing same, and a pharmaceutical composition comprising same.
PCT/KR2010/005149 2009-08-07 2010-08-05 Prasugrel disulfonate or crystalline forms thereof, method for preparing same, and pharmaceutical composition containing same WO2011016686A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0072882 2009-08-07
KR1020090072882A KR20110015254A (en) 2009-08-07 2009-08-07 Prasugrel disulfonate salts and crystals thereof

Publications (2)

Publication Number Publication Date
WO2011016686A2 WO2011016686A2 (en) 2011-02-10
WO2011016686A3 true WO2011016686A3 (en) 2011-06-30

Family

ID=43544796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005149 WO2011016686A2 (en) 2009-08-07 2010-08-05 Prasugrel disulfonate or crystalline forms thereof, method for preparing same, and pharmaceutical composition containing same

Country Status (2)

Country Link
KR (1) KR20110015254A (en)
WO (1) WO2011016686A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103772408A (en) * 2012-10-26 2014-05-07 江苏先声药物研究有限公司 Crystal of prasugrel-1,5-napadisylate

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148023B1 (en) * 1991-09-09 1998-08-17 가와무라 요시부미 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting
KR20040062965A (en) * 2001-11-21 2004-07-09 스미스클라인비이참피이엘시이 Rosiglitazone edisylates and their use as antidiabetics
KR20070095646A (en) * 2006-03-22 2007-10-01 한미약품 주식회사 Method of preparing clopidogrel 1,5-naphthalenedisulfonate and hydrate thereof
WO2007114526A1 (en) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof
CN101177430A (en) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 Hydrogenated pyridine derivative and method for preparing salt thereof
CN101255169A (en) * 2008-03-26 2008-09-03 山东大学 Prasugrel salt and preparation method thereof
WO2009066326A2 (en) * 2007-11-19 2009-05-28 Msn Laboratories Limited Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148023B1 (en) * 1991-09-09 1998-08-17 가와무라 요시부미 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting
KR20040062965A (en) * 2001-11-21 2004-07-09 스미스클라인비이참피이엘시이 Rosiglitazone edisylates and their use as antidiabetics
KR20070095646A (en) * 2006-03-22 2007-10-01 한미약품 주식회사 Method of preparing clopidogrel 1,5-naphthalenedisulfonate and hydrate thereof
WO2007114526A1 (en) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof
WO2009066326A2 (en) * 2007-11-19 2009-05-28 Msn Laboratories Limited Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
CN101177430A (en) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 Hydrogenated pyridine derivative and method for preparing salt thereof
CN101255169A (en) * 2008-03-26 2008-09-03 山东大学 Prasugrel salt and preparation method thereof

Also Published As

Publication number Publication date
KR20110015254A (en) 2011-02-15
WO2011016686A2 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2009025876A8 (en) Crystalline forms of erlotinib hcl and formulations thereof
AP2012006191A0 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same.
WO2010117738A3 (en) Solid state forms of sitagliptin salts
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2008066935A3 (en) Crystalline forms of tigecycline and processes for preparation thereof
WO2007127292A3 (en) Tigeycline crystalline forms and processes for preparation thereof
WO2008021342A3 (en) Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
AP2011005935A0 (en) New Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions comprising them.
WO2006081515A3 (en) Duloxetine hydrochloride polymorphs
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
EP2351764A4 (en) Trehalose compound, method for producing same, and pharmaceutical product containing the compound
WO2010056656A3 (en) Preparation of crystalline palonosetron hydrochloride
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2010008735A3 (en) Solid states of o-desmethylvenlaf axine salts
AP2010005343A0 (en) New dihydroindolone compounds, a process for theirpreparation and pharmaceutical compositions conta ining them.
WO2008051539A3 (en) Processes for preparing palonosetron salts
WO2009002538A3 (en) Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
PT2231598E (en) Novel diazeniumdiolate derivatives, method for the preparation thereof and pharmaceutical compositions containing the same
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2007148102A3 (en) Crystalline duloxetine hydrochloride
WO2007125521A3 (en) Polymorphic form of zoledronic acid and processes for their preparation
WO2010039885A3 (en) Crystalline forms of dexlansoprazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10806660

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10806660

Country of ref document: EP

Kind code of ref document: A2